Abstract

BackgroundDue to the widespread resistance of Plasmodium falciparum to chloroquine drug, artemisinin-based combination therapy (ACT) has been recommended as the first-line treatment. This study aims to evaluate the extent of chloroquine resistance in P. falciparum infection after the introduction of ACT. This study was carried out based on the mutation analysis in P. falciparum chloroquine resistant transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes. Identification of these molecular markers plays a significant role in monitoring and assessment of drug resistance as well as in designing an effective antimalarial drug policy in India. MethodsSixty blood samples were collected from patients infected with P. falciparum from JIPMER, Puducherry and MKCG Medical College, Odisha. Polymerase chain reaction-restriction fragment length polymorphism was performed, targeting the point mutation of K76T in pfcrt and N86Y in pfmdr1 gene. The PCR products were sequenced, genotyped and further analysed for amino acid changes in these codons. ResultsThe frequency of pfcrt mutation at 76th position was dominant for mutant T allele with 56.7% and wild type K, 43.3%. Majority of pfmdr1 86 allele were wild type, with N (90%) and mutant, Y (10%). Additionally, we found three haplotypes for CQ resistance, SVMNT, CVIET and CVIKT in association with the pfcrt gene. However, a poorly studied SNP in pfmdr1 gene (Y184F) associated with CQ resistance showed high frequency (70%) in P. falciparum isolates. ConclusionsThe point mutation K76T of pfcrt is high in P. falciparum suggesting a sustained high CQ resistance even after five years of the introduction of ACTs for antimalarial therapy. The present study suggests a strong association of CQ resistance with pfcrt T76, but not with the pfmdr1 Y86 mutation. However, sequence analysis showed that Y184F mutation on pfmdr1 gene was found to be associated with high resistance. Also, a new pfcrt haplotype ‘CVIKT’ associated with CQ resistance was found to be present in Indian strains of P. falciparum. The data obtained from this study helps in continuous monitoring of drug resistance in malaria and also suggests the need for careful usage of CQ in Plasmodium vivax malarial treatment.

Highlights

  • Malaria is a serious public health burden occurring mainly in the tropical and subtropical regions of the world

  • DNA from these isolates were analysed for CQ resistance based on the presence of K76T and asparagine replaced by tyrosine at 86th position (N86Y) mutation in pfcrt and pfmdr1 gene respectively

  • The survey of pfcrt and pfmdr1 gene fragments associated with CQ resistance study in high and low malaria endemic areas of India benefit us in understanding the molecular evolutionary changes in P. falciparum isolates

Read more

Summary

Introduction

Malaria is a serious public health burden occurring mainly in the tropical and subtropical regions of the world. This study was carried out based on the mutation analysis in P. falciparum chloroquine resistant transporter (pfcrt) and P. falciparum multidrug resistance 1 (pfmdr1) genes. Identification of these molecular markers plays a significant role in monitoring and assessment of drug resistance as well as in designing an effective antimalarial drug policy in India. A poorly studied SNP in pfmdr gene (Y184F) associated with CQ resistance showed high frequency (70%) in P. falciparum isolates. The present study suggests a strong association of CQ resistance with pfcrt T76, but not with the pfmdr Y86 mutation. Sequence analysis showed that Y184F mutation on pfmdr gene was found to be associated with high resistance. The data obtained from this study helps in continuous monitoring of drug resistance in malaria and suggests the need for careful usage of CQ in Plasmodium vivax malarial treatment

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call